Gupta Pramod 4/A
4/A · Unicycive Therapeutics, Inc. · Filed Jun 15, 2026
Research Summary
AI-generated summary of this filing
Unicycive (UNCY) EVP Pramod Gupta Receives 169,500 RSU Award
What Happened
Pramod Gupta, EVP, Pharmaceuticals and Business Development at Unicycive Therapeutics (UNCY), was granted 169,500 restricted stock units (RSUs) on 2026-05-14. The award is reported as a derivative grant at $0.00 per share (code A) — RSUs that will convert to common stock only as they vest. This is a compensation grant rather than an open-market purchase or sale.
Key Details
- Transaction date: 2026-05-14; filing (amended) date: 2026-06-15 (the Form 4 is amended).
- Grant amount: 169,500 RSUs; reported acquisition price: $0.00 (derivative award).
- Vesting per footnote: 23,542 shares vest immediately upon grant; then 4,708 shares vest monthly over 31 months beginning June 1, 2026, subject to continued service.
- Filing note: This is an amended Form 4 filed on 2026-06-15 for a transaction dated 2026-05-14 (file shows amendment; timing is after the usual 2-business-day Form 4 window).
- Shares owned after the transaction: not specified in the amended filing.
Context
RSU grants are company compensation and only become shares as they vest (they do not represent immediate market purchases or sales). Such awards are common for executives and are different from open-market buying/selling — they reflect pay and retention incentives rather than a direct trading signal.
Insider Transaction Report
- Award
Restricted Stock Unit
[F1]2026-05-14+169,500→ 169,500 totalExercise: $0.00→ Common Stock (169,500 underlying)
Footnotes (1)
- [F1]Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 23,542 shares vest upon grant and 4,708 shares vest monthly over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.